VR

Vivek Rawat

Active Director Director DIN 11195320
DIN 11195320 First appointment Jul 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Vivek Rawat

Data last updated:

Vivek Rawat is a Director at Symvivo Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11195320
Primary Designation Director
Industry Pharma
First Appointment 15 Jul 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Jul 20252025Active

Board colleagues of Vivek Rawat

NameDINCompanyDesignation
Gunjan Shukla08425411Symvivo Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Symvivo Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Vivek Rawat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vivek Rawat

Vivek Rawat currently holds 1 directorship: Symvivo Pharmaceuticals Private Limited (Director, since 15 Jul 2025).

Vivek Rawat was first appointed on 15 Jul 2025 as Director at Symvivo Pharmaceuticals Private Limited.

The current boards of Vivek Rawat's companies include Gunjan Shukla (Symvivo Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available